Vestibulocochlear Nerve Disease

Categories: Ear diseases, Neuronal diseases

Aliases & Classifications for Vestibulocochlear Nerve Disease

MalaCards integrated aliases for Vestibulocochlear Nerve Disease:

Name: Vestibulocochlear Nerve Disease 12 14
Vestibulocochlear Nerve Diseases 42 69
Cochlear Nerve Diseases 69
Acoustic Nerve Disease 12


External Ids:

Disease Ontology 12 DOID:12657
ICD10 33 H93.3 H93.3X
ICD9CM 35 388.5
MeSH 42 D000160
NCIt 47 C27207
SNOMED-CT 64 194402005 77949003
UMLS 69 C0001163

Summaries for Vestibulocochlear Nerve Disease

MalaCards based summary : Vestibulocochlear Nerve Disease, also known as vestibulocochlear nerve diseases, is related to locked-in syndrome and blastomycosis, and has symptoms including earache An important gene associated with Vestibulocochlear Nerve Disease is RTEL1 (Regulator Of Telomere Elongation Helicase 1). The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotype is Synthetic lethal with vaccinia virus (VACV) infection.

Wikipedia : 72 The vestibulocochlear nerve (auditory vestibular nerve), known as the eighth cranial nerve, transmits... more...

Related Diseases for Vestibulocochlear Nerve Disease

Diseases related to Vestibulocochlear Nerve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 locked-in syndrome 7.5 CACNA1A PIR RTEL1 SALL1 SLC9C1 VSIR
2 blastomycosis 7.2 CACNA1A PIR RTEL1 SALL1 SLC9C1 VSIR

Symptoms & Phenotypes for Vestibulocochlear Nerve Disease

UMLS symptoms related to Vestibulocochlear Nerve Disease:


GenomeRNAi Phenotypes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.8 CACNA1A PIR SALL1

Drugs & Therapeutics for Vestibulocochlear Nerve Disease

Drugs for Vestibulocochlear Nerve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4 Antiemetics Phase 4,Phase 3
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
6 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
7 Autonomic Agents Phase 4,Phase 3
8 Gastrointestinal Agents Phase 4,Phase 3
9 glucocorticoids Phase 4,Phase 3,Phase 2
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Hormones Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Methylprednisolone acetate Phase 4,Phase 3
14 Methylprednisolone Hemisuccinate Phase 4,Phase 3
15 Neuroprotective Agents Phase 4,Phase 3
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
17 Prednisolone acetate Phase 4,Phase 3
18 Prednisolone hemisuccinate Phase 4,Phase 3
19 Prednisolone phosphate Phase 4,Phase 3
20 Protective Agents Phase 4,Phase 3
21 Anti-Bacterial Agents Phase 4,Phase 2,Early Phase 1
22 Anti-Infective Agents Phase 4,Phase 2,Early Phase 1
23 Gentamicins Phase 4
24 Anti-Asthmatic Agents Phase 4,Phase 3
25 Betamethasone benzoate Phase 4
26 Betamethasone sodium phosphate Phase 4
27 Betamethasone Valerate Phase 4 2152-44-5
28 Betamethasone-17,21-dipropionate Phase 4
29 Respiratory System Agents Phase 4,Phase 3
30 Ophthalmic Solutions Phase 4
31 Tetrahydrozoline Phase 4
Ethanol Approved Phase 3 64-17-5 702
Glycerol Approved, Investigational Phase 3 56-81-5 753
Cilostazol Approved Phase 3 73963-72-1 2754
35 Complement System Proteins Phase 3
36 Micronutrients Phase 3
37 Trace Elements Phase 3
38 Ubiquinone Phase 3
39 Vitamins Phase 3
40 Fibrinolytic Agents Phase 3,Phase 2
41 Platelet Aggregation Inhibitors Phase 3,Phase 2
42 Bronchodilator Agents Phase 3
43 Phosphodiesterase 3 Inhibitors Phase 3
44 Phosphodiesterase Inhibitors Phase 3
45 Vasodilator Agents Phase 3
46 Ginkgo Nutraceutical Phase 3
Coenzyme Q10 Experimental, Nutraceutical Phase 3 303-98-0 5281915
48 Lecithin Nutraceutical Phase 3
Everolimus Approved Phase 2,Early Phase 1 159351-69-6 6442177
Miconazole Approved, Investigational, Vet_approved Phase 2,Early Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 72)

id Name Status NCT ID Phase Drugs
1 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
4 Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy Terminated NCT02373397 Phase 4
5 The Efficacy of Steroid Therapy in Vestibular Neuritis Unknown status NCT02098330 Phase 3 Ginkgo biloba & Methylprednisolone;Ginkgo biloba
6 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
7 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Recruiting NCT02333305 Phase 3
8 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
9 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
10 Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy Terminated NCT01895400 Phase 3 Renexin (cilostazol 100mg + gingko biloba extract 80 mg);Placebo
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
12 Complementary/Alternative Medicine for Abnormality in the Vestibular (Balance) System Completed NCT00032383 Phase 1, Phase 2
13 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
14 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
15 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
16 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
17 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
18 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
19 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
20 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
21 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
22 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Recruiting NCT01345136 Phase 2 RAD001, everolimus
23 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
24 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
25 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
26 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
27 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2 Aspirin;Placebo
28 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2 PTC299
29 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
30 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
31 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
32 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
33 Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs) Unknown status NCT02463695
34 Concentration and Activity of Lapatinib in Vestibular Schwannomas Unknown status NCT00863122 Early Phase 1 lapatinib
35 Vestibular System in Migrainous Vertigo Patients Unknown status NCT00901953
36 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248
37 The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis Unknown status NCT01231009 Early Phase 1 Corticosteroids
38 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231
39 NF2 Natural History Consortium Unknown status NCT00004483
40 Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users Completed NCT00725998
41 Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients Completed NCT01222728
42 Home-based Computer Gaming in Vestibular Rehabilitation Completed NCT01943955
43 Optimizing the Ocular Surface Prior to Cataract Surgery Completed NCT02766907
44 Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype Completed NCT02298270
45 Recovery of Visual Acuity in People With Vestibular Deficits Completed NCT00411216
46 Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool Completed NCT02171312
47 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma Completed NCT02963896 gentamicin
48 Safety and Effectiveness of the MED-EL Electric-Acoustic System Completed NCT00747435
49 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
50 Maintaining Cochlear Patency After VIIIth Nerve Surgery Recruiting NCT03261726

Search NIH Clinical Center for Vestibulocochlear Nerve Disease

Cochrane evidence based reviews: vestibulocochlear nerve diseases

Genetic Tests for Vestibulocochlear Nerve Disease

Anatomical Context for Vestibulocochlear Nerve Disease

MalaCards organs/tissues related to Vestibulocochlear Nerve Disease:

Brain, Testes, Liver

Publications for Vestibulocochlear Nerve Disease

Articles related to Vestibulocochlear Nerve Disease:

id Title Authors Year
Facial and vestibulocochlear nerve disease in six horses. ( 6643213 )

Variations for Vestibulocochlear Nerve Disease

Expression for Vestibulocochlear Nerve Disease

Search GEO for disease gene expression data for Vestibulocochlear Nerve Disease.

Pathways for Vestibulocochlear Nerve Disease

GO Terms for Vestibulocochlear Nerve Disease

Molecular functions related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 8.62 CACNA1A SLC9C1

Sources for Vestibulocochlear Nerve Disease

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....